Abstract
AZT, a chain terminator of DNA synthesis originally developed for chemotherapy, is now prescribed as an antihuman immunodeficiency virus (HIV) drug at 500 to 1500 mg/person/day, which corresponds to 20 to 60 μM AZT. The human dosage is based on a study by the manufacturer of the drug and their collaborators, which reported in 1986 that the inhibitory dose for HIV replication was 0.05 to 0.5 μM AZT and that for human T-cells was 2000 to 20,000 times higher, i.e. 1000 μM AZT. This suggested that HIV could be safely inhibited in humans at 20 to 60 μM AZT. However, after the licensing of AZT as an anti-HIV drug, several independent studies reported 20-to 1000-fold lower inhibitory doses of AZT for human and animal cells than did the manufacturer’s study, ranging from 1 to 50 μM. In accord with this, life threatening toxic effects were reported in humans treated with AZT at 20 to 60 μM. Therefore, we have re-examined the growth inhibitory doses of AZT for the human CEM T-cell line and several other human and animal cells. It was found that at 10 μM and 25 μM AZT, all cells are inhibited at least 50% after 6 to 12 days, and between 20 and 100% after 38 to 48 days. Unexpectedly, variants of all cell types emerged over time that were partially resistant to AZT. It is concluded that AZT, at the dosage prescribed as an anti-HIV drug, is highly toxic to human cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Avramis, V.I., W. Markson, R.L. Jackson & E. Gomperts, 1989. Biochemical pharmacology of zidovudine in human Tlymphoblastoid cells (CEM). AIDS 3: 417–422.
Bacellar, H., A. Munoz, E.N. Miller, B.A. Cohen, D. Besley, O.A. Seines, J.T. Becker & J.C. McArthur, 1994. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology 44: 1892–1900.
Bagasra, O., S.P. Hauptman, H.W. Lischner, M. Sachs & R.J. Pomerantz, 1992. Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N. Engl. J. Med. 326: 1385–1391.
Balzarini, J., P. Herdewijn & E. De Clercq, 1989. Differential patterns of intracellular metabolism of 2’,3’-didehydro-2’,3’didexoythymidine and 3’-azido-2’,3’-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264: 6127–6133.
Duesberg, P.H., 1992. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacology & Therapeutics 55: 201–277.
Duesberg, P.H., 1993. HIV and AIDS. Science 260: 1705.
Fischl, M.A., D.D. Richman, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M. Leedon, J.E. Groopman, D. Mild-van, R.T. Schooley, G.G. Jackson, D.T. Durack, D. King and the AZT Collaborative Working Group, 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 185–191.
Freiman, J.P., K.E. Helfert, M.R. Hamrell & D.S. Stein, 1993. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7: 379–385.
Furman, P.A., J.A. Fyfe, M. St Clair, K. Weinhold, J.L. Rideout, G.A. Freeman, S. Nusinoff-Lehrman, D.P. Bolognesi, S. Broder, H. Mitsuya & D.W. Barry, 1986. Phosphorylation of 3’-azido-3’deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83: 8333–8337.
Goedert, J.J., A.R. Cohen, C.M. Kessler, S. Eichinger, S.V. Seremetis, C.S. Rabkin, F.J. Yellin, P.S. Rosenberg & L.M. Ale-dort, 1994. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 344: 791–792.
Gogu, S.R., B.S. Beckman & K.C. Agrawal, 1989. Anti-HIV drugs: Comparative toxicities in mutine fetal liver and bone marrow erythroid progenitor cells. Life Sci. 45: iii-vii.
Horwitz, J.P., J. Chua & M. Noel, 1964. Nucleosides. V. The monomesylates of 1-(2’-deoxy-beta-Dlyxofuranosyl)thymidine. J. Org. Chem. 29: 2076.
Inoue, T., K. Tsushita, T. Itoh, M. Ogura, T. Hotta, M. Saneyoshi, S. Yoshida, H. Saitoh, Y. Tomoda & Y. Nagai, 1989. In vitro bone marrow toxicity of nucleoside analog against human immunodeficiency virus. Antimicrob. Agents Chemother. 33: 576–579.
Kornberg, A., 1980. DNA Replication. Freeman and Company, San Francisco.
Lemaître, M., D. Guetard, Y. Henin, L. Montagnier & A. Zerial, 1990. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res. Virol. 141: 5–16.
Mansuri, M.M., M.J.M. Hitchcock, R.A. Buroker, C.L. Bregman, I. Ghazzouli, J.V. Desiderio, J.E. Starrett, R.Z. Sterzycki & J.C. Martin, 1990. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrob. Agents Chemother. 34: 637–641.
Mir, N. & C. Costello, 1988. Zidovudine and bone marrow. Lancet ii: 1195–1196.
Physicians’ Desk Reference, 1994. Retrovir.
Piatak, M., L.C. Sang, S.C. Yang, S.J. Clark, J.C. Kappes, K.-C. Luk, B.H. Hahn, G.M. Shaw & J.D. Lifson, 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749–1754.
Richman, D.D., M.A. Fischl, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M. Leedom, J.E. Groopman, D. Mildvan, M.S. Hirsch, G.G. Jackson, D.T. Durack, S. NusinoffLehrman and the AZT Collaborative Working Group, 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 192–197.
Rubin, H. & H. Temin, 1958. A radiological study of cell-virus interaction in the Rous sarcoma. Virology 7: 75–91.
Seligmann, M., D. A. Warrell, J.-P. Aboulker, C. Carbon, J.H. Darbyshire, J. Dormont, E. Eschwege, D.J. Girling, D.R. James, J.-P. Levy, P.T.A. Peto, D. Schwarz, A.B. Stone, I.V.D. Weller, R. Withnall, K. Gelmon, E. Lafon, A.M. Swart, V.R. Aber, A.G. Babiker, S. Lhoro, A.J. Nunn & M. Vray, 1994. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343: 871–881.
Simmonds, P., P. Balfe, J.F. Peutherer, C.A. Ludlam, J.O. Bishop & A.J. Leigh-Brown, 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64: 864–872.
Sommadossi, J.-P., Z. Zhu, R. Carlisie, M.-Y. Xie, D.A. Weidner & M.H. El Kouni, 1990. Novel pharmacological approaches to the treatment of AIDS and potential use of uridine phosphorylase inhibitors. In: Advances in Chemotherapy of AIDS, pp. 63–73, R.B. Diasio & J.-P. Sommadossi (eds.) Pergamon Press Inc., New York.
Tokars, J.I., R. Marcus, D.H. Culver, C.A. Schable, P.S. McKibbe, C.I. Bandea & D.M. Bell, 1993. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann. Intern. Med. 118: 913–919.
Volberding, P.A., S.W. Lagakos, M.A. Koch, C. Pettinelli, M.W. Myers, D.K. Booth, H.H. Balfour Jr., R.C. Reichman, J.A. Bartlett, M.S. Hirsch, R.L. Murphy, W.D. Hardy, R. Soeiro, M.A. Fischl, J.G. Bartlett, T.C. Merigan, N.E. Hyslop, D.D. Richman, F.T. Valentine, L. Corey and the AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Disease, 1990. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322: 941–949.
Weiss, R., N. Teich, H. Varmus & J. Coffin, 1985. Molecular Biology of RNA Tumor Viruses. Cold Spring Harbor Press, Cold Spring Harbor, NY.
Yarchoan, R., J.M. Pluda, C.-F. Pemo, H. Mitsuya & S. Broder, 1991. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood 78: 859–884.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Chiu, D.T., Duesberg, P.H. (1996). The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. In: Duesberg, P.H. (eds) AIDS: Virus- or Drug Induced?. Contemporary Issues in Genetics and Evolution, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1651-7_11
Download citation
DOI: https://doi.org/10.1007/978-94-009-1651-7_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-3961-8
Online ISBN: 978-94-009-1651-7
eBook Packages: Springer Book Archive